These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7954401)

  • 1. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.
    Hardy B; Yampolski I; Kovjazin R; Galli M; Novogrodsky A
    Cancer Res; 1994 Nov; 54(22):5793-6. PubMed ID: 7954401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.
    Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
    Proc Natl Acad Sci U S A; 1997 May; 94(11):5756-60. PubMed ID: 9159146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune stimulatory and anti-tumor properties of anti-CD3 and BAT monoclonal antibodies: a comparative study.
    Hardy B; Kovjazin R; Raiter A; Ganor N; Novogrodsky A
    Hum Antibodies; 1997; 8(2):95-8. PubMed ID: 9289394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
    Bock SN; Cameron RB; Kragel P; Mulé JJ; Rosenberg SA
    Cancer Res; 1991 May; 51(10):2649-54. PubMed ID: 2021943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of melanoma metastases in lungs of BAT treated and peptide immunized mice.
    Feinmesser M; Raiter A; Hardy B
    Int J Oncol; 2006 Oct; 29(4):911-7. PubMed ID: 16964387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration.
    Teitz-Tennenbaum S; Li Q; Rynkiewicz S; Ito F; Davis MA; McGinn CJ; Chang AE
    Cancer Res; 2003 Dec; 63(23):8466-75. PubMed ID: 14679011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of metastases with lymphocytes treated with exogenous RNA in mice bearing B16 melanoma.
    Watanabe MA; Almeida DO; Serrano SV; Sales VS; Soares FA; de Lucca FL
    Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):393-8. PubMed ID: 9193794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
    Eisenthal A; Lafreniere R; Lefor AT; Rosenberg SA
    Cancer Res; 1987 Jun; 47(11):2771-6. PubMed ID: 3494504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
    Gold JE; Osband ME
    Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy.
    Saji H; Song W; Furumoto K; Kato H; Engleman EG
    Clin Cancer Res; 2006 Apr; 12(8):2568-74. PubMed ID: 16638867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W; He L; Cao X
    Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased tumor surveillance after adoptive T-cell therapy.
    Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
    Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.
    Gold JE; Masters TR; Osband ME
    J Surg Res; 1995 Aug; 59(2):279-86. PubMed ID: 7543632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.